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Abstract
Background: Expression of intracellular antibodies (intrabodies) has become a broadly applicable
technology for generation of phenotypic knockouts in vivo. The method uses surface depletion of
cellular membrane proteins to examine their biological function. In this study, we used this strategy
to block the transport of cell surface molecule CD147 to the cell membrane. Phage display
technology was introduced to generate the functional antibody fragment to CD147, and we
subsequently constructed a CD147-specific scFv that was expressed intracellularly and retained in
the endoplasmic reticulum by adenoviral gene transfer.
Results: The recombinant antibody fragments, Fab and scFv, of the murine monoclonal antibody
(clone M6-1B9) reacted specifically to CD147 by indirect enzyme-linked immunosorbent assays
(ELISA) using a recombinant CD147-BCCP as a target. This indicated that the Fab- and scFv-M6-
1B9 displaying on phage surfaces were correctly folded and functionally active. We subsequently
constructed a CD147-specific scFv, scFv-M6-1B9-intrabody, in 293A cells. The expression of
CD147 on 293A cell surface was monitored at 36 h after transduction by flow cytometry and
demonstrated remarkable reduction. Colocalization of scFv-M6-1B9 intrabody with CD147 in the
ER network was depicted using a 3D deconvolution microscopy system.
Conclusion: The results suggest that our approach can generate antibody fragments suitable for
decreasing the expression of CD147 on 293A cells. This study represents a step toward
understanding the role of the cell surface protein, CD147.
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Background
CD147 is a 50–60 kDa transmembrane glycoprotein. The
molecule has an external domain consisting of two
regions exhibiting the features of the immunoglobulin
superfamily [1-3]. CD147 is widely expressed in both
hematopoietic and non-hematopoietic cells and tissues
[4-7]. However, the molecule is strongly expressed on var-
ious cancer cells, thymocytes and activated T lymphocytes
[3,6,8-12]. CD147 is involved in cellular adhesion
[8,13,14], lymphocyte activation [14-16], membrane
transport [17-19] and signal transduction [20-23]. In
addition, CD147 plays a crucial role in the invasive and
metastatic activity of tumor cells [9,24,25]. Inhibition of
CD147 cell surface expression may help to elucidate these
physiological functions of CD147.
A negative regulatory function for CD147 in T cell regula-
tion has been demonstrated [14-16,26]. Recently, two
anti-CD147 mAbs, M6-1E9 and M6-1B9, which react with
the membrane-distal Ig domain, have been shown to
inhibit OKT3-induced T cell proliferation [14]. Presuma-
bly, prevention of cell division is caused by delivery of a
negative signal via CD147. Another possibility is preven-
tion of CD147 becoming associated with its cell surface
partners, which may cooperate in CD3 signaling to gener-
ate the complete activation signal. The latter hypothesis
may be investigated by blocking the expression of surface
CD147.
Intracellularly expressed antibodies (intrabodies) can
inhibit protein function in specific cellular compartments
[27]. They have the capacity to inhibit the translocation of
cell surface molecules from the endoplasmic reticulum
(ER) to the cell surface as ER-intrabodies [27-29]. Intra-
bodies offer an effective alternative to gene-based knock-
out technology [30]. This technique has several
advantages compared to RNA interference (RNAi) tech-
nology, since intrabodies possess a much longer active
half-life than RNA, are much more specific to their target
molecules [31,32] and generally do not disrupt target
gene transcription. Moreover, gene knockout and silenc-
ing techniques cannot be used to analyze domain func-
tions and post-translationally modified protein functions.
The aim of the present study was to generate an intrabody
against CD147 in order to down-regulate the cell surface
expression of CD147 and retain this surface molecule
inside the cell. Sequences encoding both variable regions
of heavy chain (VH) and light chain (VL) domains against
CD147 were cloned from hybridomas producing mono-
clonal antibody clone M6-1B9. These sequences were
joined by a flexible peptide linker sequence, allowing the
expression of scFv as a single polypeptide chain. The func-
tional activities of this intrabody, i.e. target tracing and
capturing, were verified in a human embryonic kidney cell
line, 293A, which naturally expresses CD147. This manip-
ulation of cell surface CD147 expression could serve as a
basis for the generation of CD147-down regulated cells,
and represents a step toward characterizing the role of
CD147 in regulation of lymphocyte activation and induc-
tion of matrix metalloproteinase production by tumor
cells.
Results
Construction of a phagemid vector encoding scFv-M6-1B9
The heavy, Fd, and light chain domains of anti-CD147
mAb, M6-1B9 [8], were amplified, subcloned into the
expression vector and then named as pCom3H-Fab-M6-
1B9. Subsequently, the VL and VH were amplified from
pCom3H-Fab-M6-1B9 and attached by a peptide linker to
form the scFv. The amplified product was cloned into
phagemid vector pComb3X, named pComb3X-scFv-M6-
1B9, and then transformed into E. coli TG1. The nucle-
otide sequence of the inserted fragment, scFv, was
obtained (Figure 1). The scFv construct was fused to the
carboxy-terminal domain of the minor coat protein, gpIII,
and displayed on the surface of phage particles. The
deduced amino acid sequences of variable heavy (VH) and
light (VL) chains are listed in Figure 1. The amino acid res-
idues responsible for paratope in CDR regions were sub-
sequently identified via  the WAM (for Web Antibody
Modelling) algorithm [33]. The sequence can be num-
bered following Kabat's rule [34], in order to assure suc-
cess in cloning the immunoglobulin variable domains.
Detection of phage-displayed scFv-M6-1B9
The expression of Fab- and scFv-M6-1B9 on phage parti-
cles was assessed by Western immunoblotting. Equal
amounts of each recombinant phage were fractionated by
SDS-PAGE, blotted, and probed with anti-gpIII mAb.
Wild-type gpIII has a calculated molecular mass of
approximately 44 kDa. However, a 62 kDa protein
detected in Western blots using anti-gpIII specific anti-
bodies has been previously demonstrated [35-37]. The
truncated form of gpIII is used in pComb3 vector which
has a molecular mass of 18.7 kDa. In case of Fab antibody
fusion format in the present study, Fd fragment was fused
to truncated gpIII. This resulted in migration of Fd-gpIII
fusion at 47 kDa as indicated by arrow (28.7 kDa of Fd
fused with 18.7 kDa of truncated gpIII). Likewise, the
molecular mass of scFv is also approximately 28.7 kDa
which resulted in a molecular weight of 47 kDa of scFv-
gpIII fusion protein. Thus, the immunoreactive bands of
scFv-M6-1B9- and Fab-M6-1B9-gpIII fusion protein with
the approximate molecular weight of 47 kDa were
obtained (Figure 2A). Noticeably, the band corresponding
to the scFv-gpIII fusion protein was more prominent than
the band corresponding to the Fab-M6-1B9-gpIII fusion
protein, reflecting the fact that expression of scFv was
superior to that of Fab obtained by the phage display tech-BMC Biotechnology 2008, 8:5 http://www.biomedcentral.com/1472-6750/8/5
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nique. Antigen-specific binding of phage presenting the
different antibody formats was verified by ELISA using
recombinant CD147-biotin carboxyl carrier protein
(BCCP) fusion protein as an antigen. The scFv format
demonstrated more favorable antigen-binding features
than the Fab format (Figure 2B). In contrast, VCSM13
phage prepared from non-transformed TG-1 did not gen-
erate the signal against CD147-BCCP antigen. These
Nucleotide sequence of cDNA and deduced amino acid sequence of the scFv-M6-1B9 Figure 1
Nucleotide sequence of cDNA and deduced amino acid sequence of the scFv-M6-1B9. The cDNA sequence encoding scFv-M6-1B9 was shown. 
Restriction endonuclease sites, His tags, and HA tag are indicated. The deduced amino acid sequence of scFv-M6-1B9 corresponding to the complementary 
determining regions (CDRs) in the variable regions of the L (red letters) and H (green letters) chains, which were identified by the Kabat numbering 
scheme, are indicated by gray boxes. Amino acids were numbered from the initiator methionine (M*). The amber stop codon was shown by an asterisk (*). 
The details of the CDRs region of scFv-M6-1B9 are shown as CDR1-VL C (24SV---LH35) W, CDR2-VL Y (51GT---AS 57) G, CDR3-VL C (90QQ---PL97) T, 
CDR1-VH S (153GF---MS162) W, CDR2-VH A (178IS---KG193) R, and CDR3-VH R (226FR---GAY231) W.BMC Biotechnology 2008, 8:5 http://www.biomedcentral.com/1472-6750/8/5
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results suggest that phage presenting different antibody
formats of M6-1B9 had been successfully produced and
that the scFv version was the better functional antibody
fragment.
Detection and characterization of soluble scFv-M6-1B9 
produced in E. coli
The pComb3X-scFv-M6-1B9 was subsequently trans-
formed into E. coli HB2151 to produce the soluble scFv
antibody. The presence of soluble scFv in the culture
supernatant was detected by Western immunoblotting
regarding HA and His tags. The reactive bands revealed by
anti-HA or anti-His were located at the same molecular
weight (~30 kDa) (Figure 3A). This result indicates that
soluble scFv-M6-1B9 was successfully produced by E. coli
HB2151.
The specificity of soluble scFv-M6-1B9 was analyzed by
ELISA using CD147-BCCP as antigen (Figure 3B). Various
dilutions of soluble scFv-M6-1B9 were represented the
positive signal with CD147-BCCP. No signal was detected
in the control well of survivin-BCCP (SVV-BCCP) antigen.
Subsequently, Western immunoblotting was used to con-
firm the specificity of the generated scFv-M6-1B9 against
recombinant CD147. A specific band of CD147-BCCP at
~35 kDa was detected by probing with soluble scFv-M6-
1B9 (Figure 3C). In addition, the native epitope of CD147
on the U937 cell surface was recognized by soluble scFv-
M6-1B9 using flow cytometric analysis. The mean fluores-
cence intensity (MFI) of CD147 cell surface expression on
U937 cells stained with soluble scFv-M6-1B9 was 10.42
(Figure 3D). This was similar to the value for the original
antibody, M6-1B9, which MFI was 9.21 as shown in Fig-
ure 3D. These results strongly suggested that the generated
soluble scFv-M6-1B9 carry a CD147-specific paratope
which recognized both recombinant and native CD147.
To further characterize the specificity of the produced
scFv, the inhibiting activity of soluble scFv-M6-1B9 with
the original monoclonal antibody, M6-1B9, was tested.
The optical density of mixture of soluble scFv-M6-1B9 and
mAb M6-1B9 was lower than soluble scFv-M6-1B9 alone
(Figure 4). In contrast, the irrelevant mAb MT-SVV3 did
not show the inhibition effect. This indicates that the scFv-
M6-1B9 recognized the same antigenic determinant as its
original mAb M6-1B9.
Intracellular expression of scFv-M6-1B9 intrabody abated 
cell surface expression of CD147 on 293A cells
The compatibility of scFv-M6-1B9 with a eukaryotic
expression system was examined by transducing the
recombinant adenovirus harboring scFv-M6-1B9 into
293A cells. Alteration of surface expression of CD147 in
transduced 293A cells was examined at 36 h after trans-
duction. CD147 cell surface expression was decreased in
scFv-M6-1B9 adenovirus-transduced 293A cells compared
to untransduced cells (Figure 5). In contrast, no alteration
of CD147 expression was observed on scFv-SVV3 adeno-
virus-transduced cells (Figure 5). This result revealed that
intracellular expression of scFv-M6-1B9 as intrabody
Verification of antibody phage presenting different formats Figure 2
Verification of antibody phage presenting different formats. A Recombinant phages (1013 t.u./lane) were separated on a reducing 12% SDS-PAGE. 
The gpIII protein was probed using anti-gpIII mAb. The immunoreactive bands were visualized by chemiluminescence substrate detection system. Lane 1, 
phage-displayed scFv-M6-1B9; lane 2, phage-displayed Fab-M6-1B9 and lane 3, VCSM13 helper phage. Molecular weight markers in kDa are indicated. 
Arrow indicates recombinant antibody fragment-gpIII fusion proteins (~47 kDa). B CD147-BCCP was captured on wells coated with avidin. Three differ-
ent concentrations, 1010 – 1012 t.u./ml of phage-displayed scFv-M6-1B9 and phage-displayed Fab-M6-1B9 were added and traced by peroxidase-conjugated 
anti-M13 phage mAb. VCSM13 helper phage and mAb M6-1B9 specific for CD147 [8] were used as wild-type phage control and antibody control, respec-
tively.BMC Biotechnology 2008, 8:5 http://www.biomedcentral.com/1472-6750/8/5
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could diminish CD147 expression on cell surface of intra-
body-expressing 293A cells.
Colocalization of scFv-M6-1B9 intrabody and CD147 in 
293A cells
Colocalization of scFv-M6-1B9 intrabody and CD147
within transfected 293A cells was elucidated. As shown in
Figure 6 and in the three-dimensional movies (Additional
file 1), scFv-M6-1B9 intrabody was found intracellularly
and colocalized with CD147. This result implied that
scFv-M6-1B9 protein fused with ER-retention signal was
successfully expressed and retained the CD147 molecule
inside the cell.
Detection of soluble scFv Figure 3
Detection of soluble scFv. A Soluble scFv-M6-1B9 was separated on 12% SDS-PAGE, electroblotted onto PVDF membrane, and probed with peroxi-
dase-conjugated mAb anti-HA (lane 1) and anti-His mAb (lane 2). The immunoreactive bands were visualized by ECL substrate detection system. The 
molecular weight is indicated. B CD147-BCCP (open columns) or SVV-BCCP (black columns) was captured on the avidin-coated wells. Soluble scFv-M6-
1B9 was subsequently added and the bound scFv was detected by peroxidase-conjugated mAb anti-HA. C CD147-BCCP (lane 1) or SVV-BCCP (lane 2) 
proteins were separated on 12% SDS-PAGE, electroblotted onto a PVDF membrane, and then probed with soluble scFv-M6-1B9. The scFv was detected 
using peroxidase-conjugated mAb anti-HA. The positions of molecular mass markers are shown on the left. D CD147 on U937 cells was stained with sol-
uble scFv-M6-1B9 and then probed by mouse anti-HA-biotin. Subsequently, FITC-conjugated sheep anti-mouse immunoglobulins antibody was added. 
Monoclonal antibody M6-1B9 was used as a control system for detecting CD147 on U937 cells. The immunofluorescence on cells stained with soluble 
scFv-M6-1B9 (bold line) or mAb M6-1B9 (thin line) is shown. The dashed line represents background fluorescence of negative control mAb. The y axis rep-
resents the number of events on a linear scale; the x axis shows the fluorescence intensity on a logarithmic scale.BMC Biotechnology 2008, 8:5 http://www.biomedcentral.com/1472-6750/8/5
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Discussion
CD147 plays a crucial role in several tissues, but is partic-
ularly dense on the surface of activated T-lymphocytes
[1,16] and malignant tumor cells [38-40]. Diminishing
the expression of CD147 on the cell surface could serve as
a step towards exploring the significance of CD147 in cel-
lular functions. In the present study, we successfully
employed an intrabody-based approach to reduce the
expression of CD147 on the 293A cell surface. This opens
new prospects for uncovering the functional role of
CD147.
Critical residues implicated in antigen binding from a
given antibody paratope are important for the construc-
tion of different antibody formats. The deduced amino
acid residues responsible for paratope in CDR regions of
the scFv-M6-1B9 were identified via the WAM algorithm
[33] and can be numbered following Kabat's rule [34].
These confirmed the precise cloning of the immunoglob-
ulin variable domains of anti-CD147 mAb, M6-1B9, into
the phagemid vector.
Two antibody formats, Fab and scFv, were exploited for
antibody phage display. To assess whether Fab-M6-1B9 or
scFv-M6-1B9 on gpIII of phage particles have exclusive
activities, both antibody formats were generated and eval-
uated. The expression of phage-displayed scFv-M6-1B9
was significantly greater than phage-displayed Fab-M6-
1B9, and both antibody fragments could recognize the
CD147 protein. Noticeably, the scFv format exhibited a
greater binding activity compared to the Fab format. The
expression level of scFvs in E. coli is typically higher than
Fabs and generates a more efficient antibody display on
the phage particle. The interdomain disulfide bond at the
C-terminal of the constant region, which plays an impor-
tant role in Fab stabilization, is predisposed to provide
lower production yield than scFvs [41].
Recognition of the amber stop codon between the scFv
and gpIII genes that occurs during the expression of
pComb3X-scFv-M6-1B9 in the non-suppressing HB2151
E. coli strain resulted in the production of soluble scFv-
M6-1B9 [42,43]. This antibody fragment was specifically
targeted both recombinant CD147 (non-glycosylated
form) and native CD147 (glycosylated form) expressed
on U937 cell surface. In addition, we demonstrated the
Inhibition of CD147 surface expression on 293A cells by M6-1B9 intrabody Figure 5
Inhibition of CD147 surface expression on 293A cells by M6-1B9 intrabody. 293A cells were transduced with recombinant adenovirus harboring 
scFv-M6-1B9 or scFv-SVV3. Cell surface staining of CD147 on A untransduced and B scFv-M6-1B9 or C scFv-SVV3 transduced cells was performed using 
CD147 mAb, M6-1B9 (bold lines) or irrelevant isotype matched mAb (dashed lines). PE-conjugated F(ab')2 fragment of sheep anti-mouse immunoglobulins 
antibody were used as a secondary antibody. The percentage (%) of CD147 positive cells was indicated.
Competitive binding analysis of soluble scFv-M6-1B9 and  mAb M6-1B9 Figure 4
Competitive binding analysis of soluble scFv-M6-1B9 and mAb 
M6-1B9. CD147-BCCP was added onto avidin-coated wells. The mixture 
contained soluble scFv-M6-1B9 and mAb M6-1B9 or mAb MT-SVV3 at 
ratio 1:1 was added into the well. The bound scFv was detected by perox-
idase-conjugated mAb anti-HA.BMC Biotechnology 2008, 8:5 http://www.biomedcentral.com/1472-6750/8/5
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inhibition of soluble scFv-M6-1B9 by the original anti-
body, M6-1B9. These data show that the soluble antibody
fragment contained a properly folded, bioactive paratope
which recognized both non-glycosylated and glycosylated
forms of CD147. CD147 is a highly glycosylated mem-
brane protein. The variation in its molecular weight, rang-
ing between 30 and 66 kDa, arises from different
glycosylation patterns [2]. Targeting of both glycosylated
and non-glycosylated CD147 molecules via scFv-M6-1B9
will be useful as a tool to knockdown the molecules in
various cell types.
Generation of adenoviral recombinants carrying scFv-M6-
1B9 intrabody in 293A cells was deemed successful, since
the cell surface expression of CD147 on these transduced
cells declined (Figure 5). It is an open question as to
whether this is due to the disruption of CD147 produc-
tion or the retention of CD147 within the cells. Possibly
the ER retention signal, KDEL, sequestered scFv-M6-1B9
intrabody in the ER. This sequestration resulted in the
binding of intrabody to the newly synthesized CD147 and
retains this molecule inside the cells, as demonstrated by
three-dimensional imaging. This result coincided with the
functional knockdown of major histocompatibility com-
plex I (MHC-I). Anti-MHC-I intrabody containing this ER
retention signal could reduce the surface expression of
MHC-I on human umbilical vein endothelial cells
(HUVEC) [44]. Thus the KDEL may be necessary for the
single-chain antibody protein to diminish the expression
of cell surface molecules. The remaining CD147 could be
due to the incomplete knockdown effect resulting from
transient expression of the scFv-M6-1B9 intrabody.
Immunocytochemical analysis for colocalization of CD147-intrabody Figure 6
Immunocytochemical analysis for colocalization of CD147-intrabody. The transfected 293A cells were fixed and incubated with a mixture of 
biotinylated anti-human extracellular matrix metalloproteinase inducer (EMMPRIN) mAb and rabbit anti-HA mAb. Then, cells were stained with the mix-
ture of Cy5-conjugated streptavidin and Cy3-conjugated anti-rabbit-IgG mAb. Nuclei were counterstained with DAPI (blue). Three-dimensional (3D) image 
of the transfected 293A cells was verified. A CD147 on transfected 293A cell stained with biotinylated anti-human EMMPRIN mAb (red), B scFv-M6-1B9 
intrabody in transfected 293A cell stained with rabbit anti-HA mAb (white), C GFP positive in transfected 293A cell and D overlay. For 3D image of colo-
calization of CD147-intrabody see additional file.BMC Biotechnology 2008, 8:5 http://www.biomedcentral.com/1472-6750/8/5
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Intrabodies demonstrate an alternative strategy of gene
inactivation that targets genomic DNA or mRNA. Unlike
RNAi technology, intrabodies act at the posttranslational
level and can be directed to relevant subcellular compart-
ments [27,31,32]. This technique has been employed to
diminish expression of a variety cell surface molecules
[44-46]. Downregulation of the CD147 surface molecule
on 293A cells by means of scFv intrabody expression was
achieved in the present study. Nevertheless, RNAi technol-
ogy has been successfully employed to restrain the expres-
sion of CD147 and study the function and mechanism of
CD147 in the development of tumor cell lines [25,47].
We therefore aim to introduce the intrabody approach as
an alternative method for studying the function and
mechanism of CD147 in a variety of metastatic tumors in
the near future.
Conclusion
We provide evidence that intrabody technology can be
used to diminish the expression of CD147 on 293A cells.
Assessment of the fundamental function of CD147 could
be achieved in the near future.
Methods
1. Cell culture
Hybridoma cells producing anti-CD147 mAb, M6-1B9
(isotype IgG3) [8,14] were cultured in Iscove's Modified
Dulbecco's medium (Gibco, Grand Island, NY) supple-
mented with 10% fetal bovine serum (FBS) (Gibco), 40
μg/ml gentamicin and 2.5 μg/ml amphotericin B. An
embryonic human kidney cell line (293A) (Invitrogen,
Carlsbad, CA) was cultured in Dulbecco's Modified
Eagle's medium (DMEM) (Gibco) supplemented with 10
mM non-essential amino acids, 10% FBS, penicillin (100
Units/ml), and streptomycin (100 μg/ml). The human
monocytic cell line (U937) was cultured in RPMI 1640
medium (Gibco), penicillin (100 Units/ml), and strepto-
mycin (100 μg/ml). All cells were maintained in a humid-
ified atmosphere of 5% CO2 at 37°C.
2. E. coli strains and vectors
E. coli strains, TG-1 and HB2151 were kindly provided by
Dr. A.D. Griffiths, MRC, Cambridge, UK. E. coli strains,
Origami B and XL-1 Blue were purchased from Novagen
(Madison, WI) and Stratagene (La Jolla, CA), respectively.
The pComb3HSS, pComb3X, modified pAdTrack and
pAdEasy vectors were generous gifts from Dr. C.F. Barbas
[28,29], The Scripps Research Institute, La Jolla, CA. The
pAK400cb vector was a kind gift from Dr. V. Santala (Uni-
versity of Turku, Finland).
3. Generation of Fab-M6-1B9 cDNA fragments
Total RNA was extracted from 5 × 106 M6-1B9-producing
hybridoma cells using TRIzol® (Invitrogen) according to
the manufacturer's instructions. Complementary DNA
(cDNA) was synthesized from 1μg total RNA using spe-
cific primers, i.e. heavy-chain Fd 3' primer (5'-GGG GGT
act agt CTT GGG TAT TCT AGG CTC-3'; the SpeI restriction
site at 5' overhang designated in small letters) and
murineκ light-chain 5' primers (5'-GCG CCG tct aga ATT
AAC ACT CAT TCC TGT TGA A-3'; the XbaI restriction site
at 5' overhang designated in small letters). Resulting first-
strand cDNA was used as a template for the amplification
of Fab fragments. Specific oligonucleotide primers [42]
were used to amplify heavy chain and light chain gene seg-
ments i.e. heavy-chain variable forward primer (5'-AGG
TCC AGC TGc tcg agT CTG G-3'; the XhoI restriction site at
5' overhang designated in small letters) and heavy-chain
Fd 3' primer; murine light-chain variable forward primer
(5'-CCA GTT CCg agc tcg TGA TGA CAC AGT CTC CA-3';
the SacI restriction site at 5' overhang designated in small
letters) and murineκ light-chain 3' primers. PCR amplifi-
cation was performed as formerly described [28].
4. Construction of phagemid expressing Fab-M6-1B9
The phagemid expressing Fab-M6-1B9 was constructed.
The DNA fragments were digested with SpeI/XhoI and
SacI/XbaI, respectively, and then cloned into SpeI/XhoI
and  SacI/XbaI sites of the phagemid expression vector
pComb3HSS. The ligation product was transformed into
the competent E. coli XL-1 Blue cells. The clones with both
inserts were selected on Luria-Bertani (LB) agar containing
100 μg/ml of ampicillin. The plasmid from transformed
E. coli XL-1 blue was prepared by QIAGEN Miniprep Kit
(Qiagen, Hilden, Germany) and digested with SpeI/XhoI
and SacI/XbaI. The corrected plasmid was subsequently
transformed into E. coli TG-1. The transformant bacteria
were selected on LB agar containing ampicillin (100 μg/
ml). Restriction fragment analysis of the purified plasmid
was performed using SpeI/XhoI and SacI/XbaI. The ampli-
fied product was checked for an inserted gene in the puri-
fied plasmid as described above. The ligated product was
named pCom3H-Fab-M6-1B9.
5. Conversion of a M6-1B9 specific Fab into a single chain 
antibody fragment (scFv)
IgG-specific variable heavy (VH) and light (VL) chain gene
fragments from purified pCom3H-Fab-M6-1B9 were
amplified using PCR system (Eppendorf, Germany) for 30
cycles in the first round (at 94°C for 15 sec, at 56°C for 30
sec, at 72°C for 90 sec and 10 min at 72°C for final exten-
sion), with each forward and backward oligonucleotide
primers set, i.e., VH fragments used MSCVH14 (5'-GGT
GGT TCC TCT AGA TCT TCC CTC GAG GTR AAG CTT
CTC GAG TC-3') and MSCG3_B (5'-CCT GGC CGG CCT
GGC CAC TAG TGA CAG ATG GGG CTG TTG TTG T-3')
primers, VL fragments used OmpSeq (5'-AAG ACA GCT
ATC GCG ATT GCA G-3') and MSCJK5-BL (5'-GGA AGA
TCT AGA GGA ACC ACC CCC ACC ACC GCC CGA GCC
ACC GCC ACC AGA GGA TTT CAG CTC CAG CTT GGTBMC Biotechnology 2008, 8:5 http://www.biomedcentral.com/1472-6750/8/5
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CCC-3') primers as described previously [42]. Then, the
purified fragments from QIAGEN PCR purification kit
(Qiagen) were used as templates for the second round of
PCR amplification to extend a linker. The amplified VH-
linker and VL-linker PCR products were combined in a
PCR reaction mixture. Twenty cycles (at 94°C for 15 sec,
at 56°C for 30 sec, at 72°C for 2 min and final extension
for 10 min at the same temperature) were performed.
These products were gel-purified, digested with SfiI,
cloned into phagemid vector pComb3X and transformed
into electrocompetent E. coli TG1. The transformed cells
were then grown and plated onto LB agar containing amp-
icillin. Colonies bearing the pComb3X-scFv-M6-1B9 con-
struct were confirmed by SfiI restriction enzyme digestion
and PCR. Finally, the inserted gene fragment was
sequenced using an ABI 3100 automatic sequencer.
6. Preparation of phage-displayed scFv-M6-1B9
A single colony of E. coli TG1 harboring pComb3X-scFv-
M6-1B9 was chosen from an LB agar plate containing
ampicillin for phage-displayed scFv-M6-1B9 preparation
as previously described [48]. In brief, transformed bacte-
ria were grown in 2× TY broth containing ampicillin (100
μg/ml) at 37°C with shaking at 200 rpm. The precultured
bacteria were subsequently transferred to the same
medium containing 1% (w/v) glucose, 1 mM Isopropyl-β-
D-thiogalactopyranoside (IPTG) and cultivated at 25°C
until the optical density at 600 nm (OD600) reach 0.5.
After induction, the bacterial culture was further infected
with 1012 t.u./ml of VCSM13 helper phages and left at
37°C for 30 min without shaking. The subsequent steps
were performed as described previously [48].
7. Preparation of plasmid vector encoding CD147Ex-BCCP
A pair of specific primers, CD147NdeI (5'-GAG GAG GAG
GTc ata tgG CTG CCG GCA CAG TCT TC-3' ; the NdeI
restriction site at 5' overhang designated in small letters)
and CD147EcoRI (5'-GAG GAG GAG CTg aat tcG TGG
CTG CGC ACG CGG AG-3' ; the EcoRI restriction site at 5'
overhang designated in small letters), were synthesized in
order to amplify CD147 extracellular domain coding
sequence from the phagemid pComb8-CD147Ex vector
[48] using ProofStart DNA polymerase (Qiagen). The sub-
sequent steps for protein expression using pAK400cb
backbone in E. coli Origami B strain were performed as
described previously [49,50]. The biotinylated CD147Ex-
BCCP fusion protein was detected by indirect ELISA using
mouse anti-CD147 mAbs including M6-1D4, M6-1B9,
M6-1E9, M6-1F3, M6-2B1 and M6-2F9 [8] and peroxi-
dase-conjugated goat-anti-mouse immunoglobulins
(KPL, Gaithersburg, MD).
8. Immunoassay for phage-displayed scFv-M6-1B9 by 
ELISA
Microtiter plates (NUNC, Roskilde, Denmark) were
coated with 50 μl of 10 μg/ml avidin in carbonate/bicar-
bonate buffer pH 8.6 overnight at 4°C. The plate was then
blocked with 200 μl of 2% skimmed milk in PBS for 1 h
at room temperature (RT). The wells were washed five
times with 0.05% Tween-20 in PBS. After washing, 50 μl
of 100 μg/ml BCCP fusion proteins, i.e. CD147-BCCP or
SVV-BCCP [50] in 2% skimmed milk, was added and the
mixture was incubated for 1 h at RT. Unbound antigen
was washed out and 50 μl of phage-displayed scFv-M6-
1B9 were added and incubated in a moist chamber for 1
h at RT. The plate was washed thoroughly with 0.05%
Tween 20 in PBS 5 times, and peroxidase-conjugated anti-
M13 phage mAb (Amersham Pharmacia Biotech, Buck-
inghamshire, UK) was added to each well. Wells were
then washed again prior to adding 100 μl 3,3',5,5'-tetram-
ethyl-benzidine (TMB) substrate. The OD at 450 nm was
measured by an ELISA plate reader (TECAN, Austria) after
adding 1 N HCl to stop the reaction. mAb M6-1B9 specific
for CD147 [8] was used as an antibody control in the
ELISA system.
9. Preparation of soluble scFv-M6-1B9
Soluble scFv-M6-1B9 was produced by expressing
pComb3X-scFv-M6-1B9 phagemid in the non-suppressor
E. coli strain HB2151. Transformed bacteria were grown in
10 ml of SB broth containing ampicillin (100 μg/ml) at
37°C for 18 h. Ten microlitres of precultured bacteria
were subsequently transferred to 10 ml of the same
medium containing 1% (w/v) glucose and ampicillin
(100 μg/ml), then cultivated at 37°C until the absorption
at 600 nm reached 0.5. The precultured bacteria were then
transferred to 90 ml of the same medium and cultivated at
the same temperature until the OD600 reached 1.5. Then,
IPTG was added to the culture at a final concentration of
1 mM. After induction, the bacteria were grown at 25°C
for 20 h. Cells were centrifuged at 15,000 g for 30 min at
4°C to collect the supernatant (containing extracellular
soluble scFv). Protein was precipitated with saturated
(NH4)2SO4 in an ice bath and concentrated with Amicon
Ultra centrifugal filter units (Millipore, Cork, Ireland).
Finally, the concentrated protein was reconstituted with
500 μl of 0.15 M PBS, pH 7.2. ELISA, Western immunob-
lotting and flow cytometric analysis were performed to
detect the antigen-binding affinity of soluble scFv-M6-
1B9.
10. Binding assay of soluble scFv-M6-1B9 by ELISA
Microtiter plates were coated with 50 μl of 10 μg/ml avi-
din in carbonate/bicarbonate buffer pH 8.6 overnight at
4°C. The plates were then blocked with 200 μl of 2%
bovine serum albumin (BSA) in PBS for 1 h at RT. The
wells were washed five times with 0.05% Tween-20 in PBSBMC Biotechnology 2008, 8:5 http://www.biomedcentral.com/1472-6750/8/5
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and 50 μl of 100 μg/ml BCCP fusion proteins [50] in 2%
BSA were added and incubated for 1 h at RT. The unbound
antigen was washed out. Fifty microlitres of scFv-M6-1B9
at various dilutions were added and incubated in a moist
chamber for 1 h at RT. The plates were washed thoroughly
with 0.05% Tween 20 in PBS for 5 times and peroxidase-
conjugated mAb anti-HA (Roche, Indianapolis, IN) was
added to each well. The wells were then washed again
prior to adding 100 μl TMB substrate and the OD at 450
nm measured after adding 1 N HCl to stop the reaction.
mAb M6-1B9 was used as an antibody control in the
ELISA system.
11. Competitive binding analysis of soluble scFv-M6-1B9 
and mAb M6-1B9
Microtiter plates were coated with 50 μl of 10 μg/ml avi-
din in carbonate/bicarbonate buffer (pH 8.6) and left
overnight at 4°C. The plate was then blocked with 200 μl
of 2% BSA in PBS for 1 h at RT. The wells were washed 5
times with 0.05% Tween-20 in PBS and 50 μl of 100 μg/
ml BCCP fusion proteins [50] in 2% BSA were added and
incubated for 1 h at RT. The unbound antigen was washed
out. Fifty microlitres of the mixture containing soluble
scFv-M6-1B9 at dilution 1:250 and 20 μg/ml mAb M6-
1B9 or mAb against survivin (MT-SVV3) at ratio 1:1 were
added. After incubation in a moist chamber for 1 h at RT,
the plate was washed thoroughly with 0.05% Tween 20 in
PBS for 5 times. Peroxidase-conjugated mAb anti-HA was
added to each well. The wells were then washed again
prior to adding 100 μl TMB substrate. The OD at 450 nm
was measured after adding 1 N HCl to stop the reaction.
12. Immunofluorescence analysis of the reactivity of 
soluble scFv-M6-1B9
U937 cells were adjusted to 1 × 107 cells/ml with 1% BSA-
PBS-NaN3 and blocked on ice with human AB serum at
the ratio of 1:10 for 30 min. Fifty microlitres of 1:10 dilu-
tion in 1% BSA-PBS-NaN3 of soluble scFv-M6-1B9 were
added to 50 μl of blocked cells and incubated on ice for
30 min. Cells were washed twice with 1% BSA-PBS-NaN3.
Subsequently, fifty microlitres of 20 μg/ml mouse anti-
HA-biotin (Sigma, St Louis, MO) were added and the cells
were incubated on ice for 30 min. After washing, cells
were resuspended with 20 μl 1% BSA-PBS-NaN3. FITC-
conjugated sheep anti-mouse immunoglobulins antibody
(Chemicon International, Melbourne, Australia) was then
added. Cells were incubated on ice for another 30 min.
Finally, cells were washed 3 times with 1% BSA-PBS-NaN3
and fixed with 1% paraformaldehyde-PBS. Fluorescence
reactivity of soluble scFv-M6-1B9 with CD147 on U937
cells was analyzed by flow cytometry.
13. Immunoblot analysis
Recombinant phage antibodies were separated on a 12%
SDS-PAGE gel under reducing conditions, then trans-
ferred onto a polyvinyllidene fluoride (PVDF) membrane.
The membranes were blocked with 5% skimmed milk in
PBS, and then incubated with mouse anti-gpIII mAb
(Exalpha Biologicals, Inc., Watertown, MA). After wash-
ing, peroxidase-conjugated goat anti-mouse immu-
noglobulins antibody were added to the membranes. The
peroxidase reaction was visualized using an enhanced
chemiluminescent (ECL) substrate detection system (GE
Healthcare, Buckinghamshire, UK).
To determine the binding activity of soluble scFv-M6-1B9,
BCCP fusion proteins were separated on 12% SDS-PAGE,
electroblotted onto PVDF membrane, and then were
probed with soluble scFv-M6-1B9 and traced by peroxi-
dase-conjugated mAb anti-HA. The immunoreactive
bands were visualized as described previously.
14. Assembly of intrabody construct in pAdTrackCMV
The scFv coding regions were flanked by a human κ light
chain leader sequence at the 5'-end, and a sequence
encoding the HA tag (YPYDVPDYA) and the ER retention
signal (KDEL) at the 3'-end. The intrabody coding regions
from pComb3X-scFv-M6-1B9 were then excised by diges-
tion with SfiI and cloned into modified pAdTrackCMV
[28]. This adapter fragment contains compatible SfiI sites,
which were used for cloning the scFv-M6-1B9 intrabody
against CD147 into the adenovirus vector. The generation
of recombinant adenoviruses was done essentially as pre-
viously described [51]. Briefly, 6 × 104 293A cells in 500 μl
DMEM containing 10% FBS and antibiotics were plated
on a polystyrene 24-well plate for 24 h before transfec-
tion. Transfection mixture was prepared by adding 1 μg
pAdE-scFv-M6-1B9 in 50 μl DMEM to 0.25 μl transfectin
(Bio-Rad, Hercules, CA) in 50 μl DMEM and followed by
incubation at RT for 20 min. The mixture was then added
to the cells and incubated at 37°C in 5% CO2 for 4 h. Four
hundred microlitres of DMEM containing 10% FBS and
antibiotics were added into the wells and plates were fur-
ther incubated at 37°C in 5% CO2 for 7 days. High titer
viral stocks were produced and purified using a ViraBind™
Adenovirus purification kit (Cell Biolabs, San Diego, CA).
15. Flow cytometry analysis for CD147 surface expression
Five hundred microlitres of 1.2 × 105 cells/ml 293A were
transduced with 10 MOI (~80% of the cells were infected)
of adenovirus encoding scFv-M6-1B9 intrabody. After 36
h, 293A cells were removed from 24-well tissue culture
plates and washed 3 times with PBS. Cells were then
blocked with human AB serum for 30 min on ice. Fifty
microlitres of 20 μg/ml purified mAb M6-1B9 in 1% BSA-
PBS-NaN3 were added to 50 μl of blocked cells and incu-
bated on ice for 30 min. Cells were washed twice with 1%
BSA-PBS-NaN3 and resuspended with 20 μl 1% BSA-PBS-
NaN3. Subsequently, twenty-five microlitres of PE-conju-
gated F(ab')2 fragment of sheep anti-mouse immunoglob-BMC Biotechnology 2008, 8:5 http://www.biomedcentral.com/1472-6750/8/5
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ulins antibody were added and incubated on ice for 30
min. Finally, cells were washed 3 times with 1% BSA-PBS-
NaN3 and fixed with 1% paraformaldehyde-PBS. Fluores-
cence reactivity of the stained cells was investigated by
flow cytometry. Adenovirus encoding scFv specific to sur-
vivin (scFv-SVV3) intrabody constructed by the same tech-
nique was used as transduction control.
16. Immunocytochemical analysis for CD147-intrabody 
colocalization
For analysis of CD147 and intrabodies on GFP-positive
293A, transfected cells were trypsinized and fixed for 10
min with 3.7% formaldehyde in PBS containing 50 mM
MgCl2. Fifty microlitres of 1 × 106 fixed cells were placed
on a silane-coated slide and air-dried. Following washing,
cells were permeabilized with 0.2% Triton-X 100 for 12
min. Slides were then washed in PBS containing 50 mM
MgCl2 and blocked with 1% BSA in SSC at RT for 5 min.
Then, the fixed cells were incubated with a mixture of
biotinylated anti-human extracellular matrix metallopro-
teinase inducer (EMMPRIN) mAb (0.1 μg/ml; R&D sys-
tems, Minneapolis, MN) and rabbit anti-HA mAb (Sigma)
at 4°C overnight. After washing, cells were blocked and
then incubated with the mixture of Cy5-conjugated
streptavidin (Amersham Life Sciences, Inc, Buckingham-
shire, UK) and Cy3-conjugated anti-rabbit-IgG mAb
(Sigma) at RT for 30 min. Nuclei were counterstained with
DAPI. Imaging of stained cells was performed by using a
Zeiss Apotome with an AxioCam HRM, AMCA, Cy3, Cy5
and FITC filters in combination with Planapo 63×/1.4 oil
objective lens. Images were acquired by using AXIOVI-
SION 4.4 (Carl Zeiss Canada Ltd., Toronto, ON, Canada)
in multichanel mode.
17. 3D image acquisitions
AXIOVISION 4.4 with deconvolution module and render-
ing module were used. For every fluorochrome, the 3D
image consists of a stack of 80 images with a sampling dis-
tance of 200 nm along the z and 107 nm in the xy direc-
tion. The constrained iterative algorithm option was used
[52].
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